Compare GTBP & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTBP | BNGO |
|---|---|---|
| Founded | 1965 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 12.5M |
| IPO Year | 2016 | 2018 |
| Metric | GTBP | BNGO |
|---|---|---|
| Price | $7.25 | $1.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 37.7K | ★ 378.5K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.75 | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $12.73 |
| Revenue Next Year | N/A | $34.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.22 | $1.00 |
| 52 Week High | $287.50 | $2.23 |
| Indicator | GTBP | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 34.37 |
| Support Level | $6.73 | $1.10 |
| Resistance Level | $7.97 | $1.35 |
| Average True Range (ATR) | 0.56 | 0.09 |
| MACD | 1.05 | -0.04 |
| Stochastic Oscillator | 61.47 | 4.04 |
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.